What is LIVTENCITY studying for CMV infection after transplant?

LIVTENCITY is being studied to understand its safety and effectiveness in adults with CMV infection after transplantation. The study aims to observe how this medicine works in everyday clinical settings to help patients with this condition. It is sponsored by Takeda to gather real-world data on its use.

Who may be eligible for this CMV infection clinical trial?

Adults aged 19 years or older with CMV infection or disease after transplant who have not responded to prior treatments like ganciclovir or valganciclovir may be eligible. Both men and women can participate. People previously treated with maribavir or currently in other CMV treatment trials cannot join. Please review eligibility criteria for more details.

Is there any cost to participate in this CMV infection clinical trial?

Study-related care, including the study drug and all trial visits, is provided at no cost. However, personal travel expenses and other non-study costs may vary and are not guaranteed to be covered. Participants should plan accordingly for any travel or related expenses.

Actively Recruiting

Age: 19Years +

All Genders

ID06555432

Study of LIVTENCITY Maribavir for Treating Cytomegalovirus Infection After Transplant in Adults in South Korea

Led by Takeda · Updated on 2025-11-18

168

Participants Needed

Research Sites

N/A

Total Duration

AI-Summary

What this Trial Is About

Cytomegalovirus CMV is a common virus that can cause serious illness, especially in people with weakened immune systems after a transplant. Researchers are evaluating the safety and effectiveness of LIVTENCITY Maribavir, a medicine approved in South Korea for treating CMV infection in adults after transplantation. This observational study aims to learn how LIVTENCITY works in routine clinical practice for these patients. Participants who have CMV infection or disease after a transplant and are resistant or refractory to one or more prior therapies such as ganciclovir, valganciclovir, foscarnet, or cidofovir will be treated with LIVTENCITY tablets as decided by their doctors. The study will follow participants for up to 20 weeks while they receive treatment according to approved labeling. During this approximately 5-month period, participant information will be collected without fixed hospital visit requirements, though visiting the study doctor about six times is recommended. Researchers will monitor adverse events, drug reactions, and CMV viral clearance through PCR tests at weeks 2, 8, and the end of treatment. They will also assess symptom control and collect safety data throughout the study.

CONDITIONS

Brief Title

A Study of LIVTENCITY (Maribavir) in Adults With Cytomegalovirus (CMV) Infection After Transplantation in South Korea

Who Can Participate

Age: 19Years +

All Genders

Eligibility Criteria

You may qualify if you...

Participants with post-transplant CMV infection or disease who are refractory or resistant to one or more prior therapies including ganciclovir, valganciclovir, cidofovir, or foscarnet
Participants aged 19 years or older
Participants starting their first treatment course with maribavir
Participants who voluntarily consent to participate in the study

You will not qualify if you...

Participants for whom LIVTENCITY (maribavir) is contraindicated according to the product label
Participants previously treated with maribavir in any study or as a marketed drug
Participants currently enrolled in other clinical trials for post-transplant CMV infection or receiving other experimental treatments

Research Team

Takeda Contact

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here